SciClone Pharmaceuticals, Inc.'s (SCLN) European Partner Sigma-Tau Pharmaceuticals Initiates Phase 3 ZADAXIN Hepatitis C Triple Therapy Trial; First Patients Enrolled And Receiving Treatment 
10/19/2005 5:08:49 PM

SAN MATEO, Calif.--(BUSINESS WIRE)--Dec. 23, 2004--SciClone Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced that Sigma-Tau, its European development and marketing partner for ZADAXIN(R), has begun enrolling patients infected with the hepatitis C virus (HCV) in a multi-center European phase 3 clinical trial evaluating the triple therapy combination of ZADAXIN, pegylated interferon alpha and ribavirin. Currently, Sigma-Tau estimates completing enrollment of the 550-patient trial by the end of 2005 and results may be reported by the end of 2007.